[1] JIULONG LI, HUAN MENG* Pulmonary Delivery of Specialized Pro-Resolving Mediators-Based Nanotherapeutics Attenuates Pulmonary Fibrosis in Preclinical Animal Models[J]. ACS Nano, 2023, 17 16: 15354-15370. DOI:
10.1021/acsnano.2c10388[2] ANTONIO RECCHIUTI. Resolvin D1 and D2 reduce SARS-CoV-2-induced inflammatory responses in cystic fibrosis macrophages[J]. FASEB Journal, 2021, 35 4. DOI:
10.1096/fj.202001952r[3] LUIZA OLIVEIRA PERUCCI PHD. Pre-eclampsia is associated with reduced resolvin D1 and maresin 1 to leukotriene B4 ratios in the plasma[J]. American Journal of Reproductive Immunology, 2019, 83 2. DOI:
10.1111/aji.13206[4] PARASKEVI KRASHIA. Author Correction: Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat model of Parkinson’s disease[J]. Nature Communications, 2019. DOI:
10.1038/s41467-019-12538-2[5] ELISA BISICCHIA. Resolvin D1 Halts Remote Neuroinflammation and Improves Functional Recovery after Focal Brain Damage Via ALX/FPR2 Receptor-Regulated MicroRNAs.[J]. Molecular Neurobiology, 2018: 6894-6905. DOI:
10.1007/s12035-018-0889-z[6] LUCA NAVARINI. Role of the Specialized Proresolving Mediator Resolvin D1 in Systemic Lupus Erythematosus: Preliminary Results.[J]. Journal of Immunology Research, 2018: 5264195. DOI:
10.1155/2018/5264195